MedTrace Logo

Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

NCT01909414 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-11-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of two HIV vaccines in HIV-1-infected young adults who are taking anti-HIV medications and have very low virus levels. This study will also look at how the immune system responds to the vaccines.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

GEO-D03 DNA Vaccine

DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.

BIOLOGICAL

MVA/HIV62B Vaccine

MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.

BIOLOGICAL

Placebo for DNA GEO-D03

Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.

BIOLOGICAL

Placebo for MVA/HIV62B Vaccine

Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Thomas Greenough, MD · University of MA Medical School (UMMS)-II Biotech

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2014-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01909414 on ClinicalTrials.gov